Walleye Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Walleye Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-74,548	Closed	-$435K	–	4607
2022 Q4	$435K	Buy	+74,548	New	+$392K	0.01%	1541
2022 Q3	–	Sell	-199,500	Closed	-$840K	–	3672
2022 Q2	$840K	Buy	+199,500	New	+$789K	0.02%	740
2021 Q3	–	Sell	-69,089	Closed	-$292	–	1909
2021 Q2	$292	Buy	69,089 +15,163	+28%	+$64.2K	0.01%	958
2021 Q1	$269	Buy	+53,926	New	+$436K	0.02%	818

Walleye Capital's CNCE Position: Q1 2023 in Review

Walleye Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 74,548 shares — an estimated $435K sold.

Walleye Capital first reported a position in CNCE in Q1 2021 and held it in 4 quarters. The position peaked at $840K in Q2 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

Walleye Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Walleye Capital sold 74,548 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $435K.
Walleye Capital first reported a position in Concert Pharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
Walleye Capital's Concert Pharmaceuticals, Inc. position peaked at $840K in Q2 2022.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Walleye Capital's 13F filing for Q1 2023, filed 15 May 2023.